Lynx Biosciences awarded a National Cancer Institute Phase I SBIR grant

We've received $268,841 of funding through our first Phase I SBIR grant! This will allow us to 1) conduct a small prospective clinical trial to further validate our technology for bortezomib, and 2) standardize bonding and fabrication of our device for mid-volume production and testing of other drugs.

Stay tuned, we hope to have more exciting updates soon.

Chorom PakComment